SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Genomma Lab Internacional, S.A.B. de C.V. GNMLF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • MX • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $1.08. It has a SharesGrow Score of 78/100, indicating a strong investment profile with 4 out of 7 criteria passed.

Financials: revenue is $973M, +579%/yr average growth. Net income is $89M, growing at +710.9%/yr. Net profit margin is 9.2% (thin). Gross margin is 62.8% (+2.4 pp trend).

Balance sheet: total debt is $425M against $616M equity (Debt-to-Equity (D/E) ratio 0.69, moderate). Current ratio is 1.77 (strong liquidity). Debt-to-assets is 32.1%. Total assets: $1.3B.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 100/100 (Pass), Health 67/100 (Partial), Moat 70/100 (Pass), Future ?/100 (Fail), Income 45/100 (Partial).

GNMLF SharesGrow Score Overview

80/100

SharesGrow Score

Strong investment profile

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 100/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 70/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 45/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GNMLF

GNMLF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

GNMLF: +579%/yr revenue is, +710.9%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

GNMLF: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet GNMLF: Debt-to-Equity (D/E) ratio 0.69 (moderate), Current ratio is 1.77 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

GNMLF: Gross margin is 62.8% (+2.4 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 70/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

GNMLF: Net profit margin is 9.2%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.91-1.43

Volume5K

Avg Volume (30D)120

Market Cap$1.05B

Beta (1Y)0.55

Dividend Yield$0.0425

Share Statistics

EPS (TTM)0.09

Shares Outstanding$974.17M

IPO Date2012-05-04

Employees1,605

CEOJuan Marco Sparvieri

Financial Highlights & Ratios

Revenue (TTM)$973.01M

Gross Profit$611.4M

EBITDA$227.93M

Net Income$89.16M

Operating Income$206.9M

Total Cash$158.62M

Total Debt$424.54M

Net Debt$265.92M

Total Assets$1.32B

Price / Earnings (P/E)11.8

Price / Sales (P/S)1.08

Analyst Forecast

Company Info

CountryMX

ExchangeOther OTC

CurrencyUSD

ISINMX01LA010006

Price Chart

GNMLF

Genomma Lab Internacional, S.A.B. de C.V. ↗ · Other OTC

Healthcare • Drug Manufacturers - Specialty & Generic

0.91 52WK RANGE 1.43

People Also View

Sumitomo Pharma Co., Ltd.

Organogenesis Holdings Inc.

Lifecore Biomedical, Inc.

Alpha Teknova, Inc.

Orexo AB (publ)

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message